Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.

Literature DB >> 18613203

Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.

Andrew Z Wang¹, Vaishali Bagalkot, Christophoros C Vasilliou, Frank Gu, Frank Alexis, Liangfang Zhang, Mariam Shaikh, Kai Yuet, Michael J Cima, Robert Langer, Philip W Kantoff, Neil H Bander, Sangyong Jon, Omid C Farokhzad.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18613203 PMCID： PMC3131111 DOI： 10.1002/cmdc.200800091

Source DB: PubMed Journal: ChemMedChem ISSN： 1860-7179 Impact factor: 3.466

× No keyword cloud information.

38 in total

1. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors: Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt
Journal: Blood Date: 2005-08-25 Impact factor: 22.113

2. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates.

Authors: Liangfang Zhang; Aleksandar F Radovic-Moreno; Frank Alexis; Frank X Gu; Pamela A Basto; Vaishali Bagalkot; Sangyong Jon; Robert S Langer; Omid C Farokhzad
Journal: ChemMedChem Date: 2007-09 Impact factor: 3.466

3. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate.

Authors: Sun Hwa Kim; Ji Hoon Jeong; Ki Woo Chun; Tae Gwan Park
Journal: Langmuir Date: 2005-09-13 Impact factor: 3.882

4. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

Authors: Omid C Farokhzad; Jianjun Cheng; Benjamin A Teply; Ines Sherifi; Sangyong Jon; Philip W Kantoff; Jerome P Richie; Robert Langer
Journal: Proc Natl Acad Sci U S A Date: 2006-04-10 Impact factor: 11.205

5. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.

Authors: Omid C Farokhzad; Sangyong Jon; Ali Khademhosseini; Thanh-Nga T Tran; David A Lavan; Robert Langer
Journal: Cancer Res Date: 2004-11-01 Impact factor: 12.701

6. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.

Authors: J K Troyer; M L Beckett; G L Wright
Journal: Prostate Date: 1997-03-01 Impact factor: 4.104

7. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245

8. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245

9. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.

Authors: Myron S Czuczman; Robin Weaver; Baha Alkuzweny; Judy Berlfein; Antonio J Grillo-López
Journal: J Clin Oncol Date: 2004-10-13 Impact factor: 44.544

10. Sensitive, noninvasive detection of lymph node metastases.

Authors: Mukesh G Harisinghani; Ralph Weissleder
Journal: PLoS Med Date: 2004-12-28 Impact factor: 11.069

88 in total

Review 1. Cell-specific aptamer-mediated targeted drug delivery.

Authors: Jiehua Zhou; John J Rossi
Journal: Oligonucleotides Date: 2010-12-23

Review 2. GCPII imaging and cancer.

Authors: C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal: Curr Med Chem Date: 2012 Impact factor: 4.530

Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.

2. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates.

3. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate.

4. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

5. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.

6. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.

7. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

8. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

9. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.

10. Sensitive, noninvasive detection of lymph node metastases.

Review 1. Cell-specific aptamer-mediated targeted drug delivery.

Review 2. GCPII imaging and cancer.

Review 3. Tumor-targeted drug delivery with aptamers.

Review 4. Molecular imaging with nucleic acid aptamers.

Review 5. Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates.

Review 6. Targeted delivery with peptidomimetic conjugated self-assembled nanoparticles.

Review 7. Design strategies for physical-stimuli-responsive programmable nanotherapeutics.

Review 8. Aptamer-conjugated nanomaterials and their applications.

Review 9. Current progress of aptamer-based molecular imaging.

Review 10. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging.